What is raltegravir, and what is it used for?
Raltegravir is an antiretroviral medicine used to treat HIV infection. It belongs to the drug class called integrase strand transfer inhibitors (INSTIs), which block HIV from integrating its genetic material into a patient’s cells.
How does raltegravir work?
Raltegravir targets HIV integrase, an enzyme the virus needs to insert viral DNA into the host cell. By inhibiting this “strand transfer” step, raltegravir reduces the ability of HIV to establish infection and replicate.
What are the common side effects people report?
Common side effects reported for raltegravir include headache and gastrointestinal effects such as nausea. As with other antiretrovirals, side effects vary by patient and regimen.
How is raltegravir typically taken?
Raltegravir is taken as an oral medication as part of a combination antiretroviral therapy regimen. The exact dosing schedule depends on the formulation and the patient’s clinical situation.
How does raltegravir compare with other HIV integrase inhibitors?
Raltegravir is in the same broader category as other INSTIs (for example, dolutegravir and bictegravir). Differences among these medicines generally involve dosing schedules, drug–drug interaction profiles, and how they perform across specific patient groups.
What about patents and exclusivity—where can I check?
For patent and exclusivity details tied to specific raltegravir products, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/